

REMARKSThe Restriction Requirement

The Examiner has required restriction to one of the following Groups under 35 U.S.C. §121:

I. Claims 1-5, 10-13 (in part) and 14-24 (in part) drawn to compounds, compositions and isosteres of Formula I, Formula I-A, Formula I-B, Formula I-C, and Formula I-D, classified in various subclasses of classes 514 and 548.


II. Claims 6-9, 10-13 (in part) and 14-24 (in part) drawn to compounds, compositions and isosteres of Formula II, Formula II-A, Formula II-B, Formula II-C, and Formula II-D, classified in various subclasses of 514 and 548.

III. Claims 25-74 drawn to various methods of using, identifying, or producing compounds capable of associating with proteins and methods of treating various diseases, classified in various subclasses of class 514.

In response, applicants elect Group I, without traverse, for further prosecution in this application. This election is made expressly without waiver of applicants' rights to continue to prosecute and to obtain claims to the non-elected subject matter either in this application or in other applications claiming benefit herefrom.


Election of Species

The Examiner has also requested an election of species. In response to the species election requirement, applicants provisionally elect compound I-3 (specification page 24) having the following structure:



I-3

The Examiner has also requested "an exact definition of each substitution on the base molecule, wherein a single member at each substituent group or moiety is selected." In response to the Examiner's request, applicants elect the following groups for the radicals indicated in Formula I:



I

X is -CH₂-;

m is zero; and

Q is 4-methylbenzoate.

Claims 1-5, 10-13, and 14-24 read on the elected species.

Pending allowance of claims 1-5, 10-13, and 14-24, applicants request the rejoinder of claims 25-74 (Group III) pursuant to MPEP §821.04.

In view of the above, applicants request that the Examiner examine claims 1-5, 10-13, and 14-24 (Group I) in this application. Applicants request favorable consideration and early allowance of the pending claims.

Conclusion

Applicants request that the Examiner enter the above election, and allow the pending claims to pass to issue.

Respectfully submitted,



Michael C. Badia
Registration No. 51,424
Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, MA 02139-4242
Tel.: (617)444-6467
Fax.: (617)444-6483
Customer No. 27916